Nasdaq · CIK 0001844417
ESLA Estrella Immunopharma, Inc.
Insider trading from SEC Form 4. Last filing Aug 26, 2026. Close $0.33 on Oct 12, 2026, 0% from the 52-week low and -89% from the high.
In brief
Estrella Immunopharma, Inc. (ESLA) has 5 SEC Form 4 filings on file from 2 insiders, the latest filed on Aug 26, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
1 open-market trade has been scored at ESLA. The newest: Jiandong Xu (Chief Financial Officer) bought $2,594 of stock on Sep 11, 2025, filed Apr 29, 2026, scored 17 (weak).
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Estrella Immunopharma, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 17Weak | Jiandong Xu Chief Financial Officer buy | $2,594 2,100 shares | +1% | - |
Transactions
Every row filed, 11 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 25, 2026 | Cheng Liu CEO | MOption exercise Common Stock, par value $0.0001 per share | +100,000 | $0.82 | $82k | 397,437 | Aug 26, 2026 |
| Aug 25, 2026 | Cheng Liu CEO | MOption exercise Incentive Stock Optionderivative | +100,000 | $0.00 | $0 | 900,000 | Aug 26, 2026 |
| Aug 18, 2026 | Jiandong Xu Chief Financial Officer | MOption exercise Common Stock, par value $0.0001 per share | +100,000 | $0.82 | $82k | 365,488 | Aug 25, 2026 |
| Aug 18, 2026 | Jiandong Xu Chief Financial Officer | MOption exercise Incentive Share Optionderivative | -100,000 | - | - | 390,796 | Aug 25, 2026 |
| Sep 11, 2025 | Jiandong Xu Chief Financial Officer | POpen-market purchase Common Stock, par value $0.0001 per share | +100 | $1.04 | $104 | 264,588 | Apr 29, 2026 |
| Sep 22, 2025 | Jiandong Xu Chief Financial Officer | POpen-market purchase Common Stock, par value $0.0001 per shareindirect: By Spouse | +1,000 | $1.16 | $1,160 | 16,700 | Apr 29, 2026 |
| Oct 7, 2025 | Jiandong Xu Chief Financial Officer | POpen-market purchase Common Stock, par value $0.0001 per share | +1,000 | $1.33 | $1,330 | 265,488 | Apr 29, 2026 |
| Oct 30, 2024 | Jiandong Xu Chief Financial Officer | AGrant or award Incentive Share Optionderivative | +490,796 | - | - | 490,796 | Feb 14, 2025 |
| Oct 30, 2024 | Cheng Liu Chief Executive Officer | AGrant or award Incentive Share Optionderivative | +490,796 | - | - | 490,796 | Feb 14, 2025 |
| Oct 30, 2024 | Jiandong Xu Chief Financial Officer | AGrant or award Nonstatutory Share Optionderivative | +509,204 | - | - | 509,203 | Feb 14, 2025 |
| Oct 30, 2024 | Cheng Liu Chief Executive Officer | AGrant or award Nonstatutory Share Optionderivative | +509,204 | - | - | 509,203 | Feb 14, 2025 |
Questions about ESLA
Answered from the filings on this page, as of the latest one.
Are insiders buying ESLA?
No. In the last 90 days no insider at Estrella Immunopharma, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade ESLA on the open market?
Jiandong Xu (Chief Financial Officer) bought $2,594 of ESLA on Sep 11, 2025 and filed the Form 4 on Apr 29, 2026. InsiderTell scored 17 (weak).
How many insiders file Form 4 at Estrella Immunopharma, Inc.?
2 people have filed a Form 4 at Estrella Immunopharma, Inc., among them Cheng Liu (CEO), Jiandong Xu (Chief Financial Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.